Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 10, 2014, Pages 2819-2825

  Charpentier, Charlotte ^a,b   Choquet, Marion ^b   Joly, Véronique ^a,b   Yeni, Patrick ^a,b   Visseaux, Benoit ^a,b   Caseris, Marion ^b   Brun Vézinet, Françoise ^b   Yazdanpanah, Yazdan ^a,b   Peytavin, Gilles ^a,b   Descamps, Diane ^a,b   Landman, Roland ^a,b  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Clinical cohort; HIV; Plasma drug concentrations; Residual viraemia

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; ANTIVIRAL RESISTANCE; DRUG EFFECTS; DRUG MONITORING; GENETICS; GENOTYPE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; RISK FACTOR; TIME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84929942164     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku211     Document Type: Article

References (24)

1. United States Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. http://aidsinfo.nih.gov/guidelines. (28 April 2014, date last accessed).
2. Doyle T, Smith C, Vitiello P et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54: 724-32.
3. Henrich TJ,Wood BR, Kuritzkes DR. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load ,48 copies/mL. PLoS One 2012; 7: e50065.
4. Widdrington J, Payne B, Medhi M et al. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011; 62: 87-92.
5. Charpentier C, Landman R, Laouénan C et al. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother 2012; 67: 2231-5.
6. Jung BH, Rezk NL, Bridges AS et al. AD. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21: 1095-104.
7. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
8. Elzi L, Erb S, Furrer H et al. Choice of initial combination antiretroviral therapy in individuals with HIV infection: determinants and outcomes. Arch Intern Med 2012; 172: 1313-21.
9. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
10. Sax PE, DeJesus E, Mills A et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
11. Cohen C, Wohl D, Arribas J et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 2014; 28: 989-97.
12. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18.
13. Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97.
14. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-55.
15. DeJesus E, Rockstroh JK, Henry K et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
16. Routman JS, Willig JH, Westfall AO et al. Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clin Infect Dis 2010; 50: 574-84.
17. Mugavero MJ, May M, Ribaudo HJ et al. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr 2011; 58: 253-60.
18. Pascual-Pareja JF, Martínez-Prats L, Luczkowiak J et al. Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy. J Clin Microbiol 2010; 48: 1911-2.
19. Mavigner M, Delobel P, Cazabat M et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4: e7658.
20. Bastard JP, Soulié C, Fellahi S et al. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 2012; 17: 915-9.
21. Haïm-Boukobza S, Morand-Joubert L, Flandre P et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 2011; 25: 341-4.
22. Bonora S, Nicastri E, Calcagno A et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009; 81: 400-5.
23. Rimsky L, Van Eygen V, Hoogstoel A et al. 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther 2013; 18: 967-77.
24. Sax PE, Tierney C, Collier AC et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204: 1191-201.